Item 2.02 Results of Operations and Financial Condition

On March 17, 2023, Pear Therapeutics, Inc. (the "Company") withdrew its revenue and operating guidance for fiscal 2022 and 2023. The Company does not plan to hold a fourth quarter and full year 2022 earnings conference call and webcast.

Item 7.01. Regulation FD Disclosure

On March 17, 2023, the Company issued a press release announcing that it is engaged in a process to explore strategic alternatives to maximize shareholder value. A copy of the Company's press release is included in this Report as Exhibit 99.1 and is incorporated herein by reference.

The information in this Current Report, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits
 Exhibit No.      Description

          99.1      Press Release dated March 1    7    , 2023
           104    Inline XBRL for the cover page of this Current Report on Form 8-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses